Menu

BENIGN BONE TUMORS:
WHY USE CERAMENT

CERAMENT augments the management of bone tumors

Injectability

Flowability

Radiopacity

Remodels into host bone within 6-12 months

For benign bone tumors requiring surgical intervention either as a result of pathologic fracture or the risk of fracture, CERAMENT®|BONE VOID FILLER offers injectability through a 16G needle, flowability and radiopacity, making it ideal for either open or percutaneous surgery and offering complete void filling. 

CERAMENT|BONE VOID FILLER remodels into host bone within 6-12 months, reducing the risk of re-fracture.

REFERENCES

Nilsson et al. The composite of hydroxyapatite and calcium sulphate: a review of preclinical evaluation and clinical applications. Expert Rev. Med. Devices 10(5), 675-684, 2013

CERAMENT®|BONE VOID FILLER Bone healing technical monograph - PR 0278-01 EN

CERAMENT®|BONE VOID FILLER Instructions for Use – IFU 0004-08

Abramo et al. Osteotomy of dorsally displaced malunited fractures of the distal radius: No loss of radiographic correction during healing with a minimally invasive fixation technique and an injectable bone substitute. Acta Orthop 79:262-268, 2008

Bark et al. Case Report: Arthroscopic-Assisted Treatment of a Reversed Hill-Sachs Lesion: Description of a New Technique Using Cerament. Case Reports in Orthopedics, Volume 2015, Article ID 789203, 5 pages. http://dx.doi.org/10.1155/2015/789203

Kaczmarczyk et al. Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study. BMC Musculoskeletal Disorders (2015) 16:369. DOI 10.1186/s12891-015-0828-3